Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMpower150
  • Sponsors Chugai Pharmaceutical; Genentech; Roche

Most Recent Events

  • 12 Sep 2023 Results of pooled analysis fromIMpower150, IMpower131, IMpower130; analyzing prognostic value of Lung Immune Prognostic Index (LIPI) in 1st-line CT +/- IT +/- antiangiogenics (AA), and its potential role in guiding treatment selection. presented at the 24th World Conference on Lung Cancer
  • 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 19 Apr 2023 Results of digital and manual PD-L1 TC scores were compared and interrogated for their respective potential to predict efficacy to atezolizumab combination treatments, presented at the 114th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top